Ovarian Cancer Market Research Reports RSS

Sort By :
TITLE Price Buy Now More options

Ovarian Cancer – Pipeline Review, H1 2013


Global Markets Direct’s, ''Ovarian Cancer Pipeline Review, H1 2013'', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Ovarian Cancer, co...

$ 2500

Epithelial Ovarian Cancer – Pipeline Review, H1 2013


Epithelial Ovarian Cancer – Pipeline Review, H1 2013 Summary Global Markets Direct’s, ''Epithelial Ovarian Cancer - Pipeline Review, H1 2013'', provides an overview of the indication’s therapeutic pipeline. This report provides information on the

$ 2000

Ovarian Cancer Global Clinical Trials Review, H2, 2012


Ovarian Cancer Global Clinical Trials Review, H2, 2012 Summary GlobalData''s clinical trial report, “Ovarian Cancer Global Clinical Trials Review, H2, 2012" provides data on the Ovarian Cancer clinical trial scenario. This report provides elemen

$ 2500

Ovarian Cancer – Pipeline Review, H2 2012


Ovarian Cancer – Pipeline Review, H2 2012 Summary Global Markets Direct’s, ''Ovarian Cancer - Pipeline Review, H2 2012'', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic developme

$ 2500

Metastatic Ovarian Cancer – Pipeline Review, H2 2012


Metastatic Ovarian Cancer – Pipeline Review, H2 2012 Summary Global Markets Direct’s, ''Metastatic Ovarian Cancer - Pipeline Review, H2 2012'', provides an overview of the indication’s therapeutic pipeline. This report provides information on the

$ 2000

Global Ovarian Cancer Drugs Market 2011-2015


TechNavio's analysts forecast the Global Ovarian Cancer Drugs market to grow at a CAGR of 13.1 percent over the period 2011-2015. One of the key factors contributing to this market growth is the increasing prevalence of ovarian cancer. The Glo...

$ 1500

Epidemiology: Ovarian Cancer – Stable or declining in younger women and increasing among older women


Incident and prevalent cases of ovarian cancer will increase across the seven major markets between 2011 and 2021. In all markets, these increases will be primarily due to the underlying population age structure. This trend is driven by the increa...

$ 3800

Clinical Trials Recruitment in Orphan Diseases - Patient Numbers in Ovarian Cancer Trials Exceed Other Orphan Diseases in Oncology


Report SummaryClinical Trial Recruitment in Orphan Diseases - Patient Numbers in Ovarian Cancer Trials Exceed Other Orphan Diseases in OncologyGBI Research, the leading business intelligence pro...

$ 3500

Avastin (Ovarian Cancer) – Analysis and Forecasts to 2020


GlobalData’s pharmaceuticals report, “Avastin (Ovarian Cancer) - Analysis and Forecasts to 2020” provides Avastin sales forecasts for US, EU5 and Japan. In additio

$ 2000

Gemzar (Ovarian Cancer) – Analysis and Forecasts to 2020


GlobalData’s pharmaceuticals report, “Gemzar (Ovarian Cancer) - Analysis and Forecasts to 2020” provides Gemzar sales forecasts for US, EU5 and Japan. In addition,

$ 2000

Farletuzumab (Ovarian Cancer) – Analysis and Forecasts to 2020


GlobalData’s pharmaceuticals report, “Farletuzumab (Ovarian Cancer) - Analysis and Forecasts to 2020” provides Farletuzumab sales forecasts for US, EU5 and Ja

$ 2000

Votrient (Ovarian Cancer) – Analysis and Forecasts to 2020


GlobalData’s pharmaceuticals report, “Votrient (Ovarian Cancer) - Analysis and Forecasts to 2020” provides Votrient sales forecasts for US, EU5 and Japan. In addi

$ 2000

Hycamtin (Ovarian Cancer) – Analysis and Forecasts to 2020


GlobalData’s pharmaceuticals report, “Hycamtin (Ovarian Cancer) - Analysis and Forecasts to 2020” provides Hycamtin sales forecasts for US, EU5 and Japan. In addi

$ 2000

Opaxio (Ovarian Cancer) – Analysis and Forecasts to 2020


GlobalData’s pharmaceuticals report, “Opaxio (Ovarian Cancer) - Analysis and Forecasts to 2020” provides Opaxio sales forecasts for the US. In addition, it covers d

$ 2000

Doxil/Caelyx (Ovarian Cancer) – Analysis and Forecasts to 2020


GlobalData’s pharmaceuticals report, Doxil/Caelyx (Ovarian Cancer) - Analysis and Forecasts to 2020” provides Doxil/Caelyx sales estimates for the US, EU and Japan. In addition, it covers detailed clinical assessment of the drug...

$ 2000

Vargatef (Ovarian Cancer) – Analysis and Forecats to 2020


GlobalData’s pharmaceuticals report, “Vargatef (Ovarian Cancer) - Analysis and Forecats to 2020” provides Vargatef sales forecasts for the US and EU5. In addition,

$ 2000

Karenitecin (Ovarian Cancer) – Analysis and Forecast to 2020


GlobalData’s pharmaceuticals report, "Karenitecin (Ovarian Cancer) - Analysis and Forecasts to 2020” provides Karenitecin sales estimates for the US, EU and Jap

$ 2000

Paclical (Ovarian Cancer) – Analysis and Forecasts to 2020


GlobalData’s pharmaceuticals report, "Paclical (Ovarian Cancer) - Analysis and Forecasts to 2020” provides Paclical sales estimates for the US and EU5. In additio

$ 2000

Paclitaxel (Ovarian Cancer) – Analysis and Forecasts to 2020


GlobalData’s pharmaceuticals report, "Paclitaxel (Ovarian Cancer) - Analysis and Forecasts to 2020” provides Paclitaxel sales forecasts for the US, EU and Japan

$ 2000

Cisplatin (Ovarian Cancer) – Analysis and Forecasts to 2020


GlobalData’s pharmaceuticals report, "Cisplatin (Ovarian Cancer) - Analysis and Forecasts to 2020” provides Cisplatin sales forecasts for the US, EU and Japan. I

$ 2000

Live Chat Support
Connect With Us
Email: sales@reportsandreports.com Call : + 1 888 391 5441
Subscription Option

Use our subscription option and keep yourself updated about the latest industry analysis reports. We have research reports for over 5000 micro markets; you can access and utilize them at economical budgets.

More about our Subscription option
Email Alerts

Get Email alerts about market research reports from industries and publishers of your interest:

> Live Chat
Live Chat by Comm100